BackTable Urology
by BackTable
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 6 chart positions in 6 markets.
By chart position
- 🇨🇦CA · Medicine#1755K to 30K
- 🇬🇧GB · Medicine#1855K to 30K
- 🇲🇽MX · Medicine#9910K to 30K
- 🇵🇹PT · Medicine#4710K to 30K
- 🇹🇷TR · Medicine#103500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
9.3K to 38K🎙 Daily cadence·297 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
31K to 126K🇨🇦24%🇬🇧24%🇲🇽24%+3 more - Active Followers
Loyal subscribers who consistently listen
9.3K to 38K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 20 epsHosts
Recent guests
Recent episodes
Ep. 318 Exploring Neuromodulation: Sacral vs Tibial Approaches with Dr. Ken Peters and Dr. Tracey Wilson
Jul 21, 2026
1h 00m 00s
Ep. 317 Focal Therapy in Prostate Cancer Treatment with Dr. George R. Schade
Jul 16, 2026
47m 53s
Ep. 316 Bladder Cancer in the Community: Meeting Patients Where They Are with Dr. Adam J. Gadzinski
Jul 14, 2026
49m 07s
Ep. 315 Private Equity's Impact on Urology Practices with Dr. Benjamin Lowentritt
Jul 10, 2026
48m 45s
Ep. 314 Exploring PARP Inhibitor Combinations in Prostate Cancer with Dr. Rana McKay and Dr. Emmanuel Antonarakis
Jul 7, 2026
51m 39s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/21/26 | neuromodulationsacral neuromodulation+4 | Dr. Ken PetersDr. Tracey Wilson | NusperaSociety of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction | — | neuromodulationsacral neuromodulation+5 | — | 1h 00m 00s | ||
| 7/16/26 | focal therapyprostate cancer+4 | Dr. George R. Schade | University of Washington | — | focal therapyprostate cancer+5 | — | 47m 53s | ||
| 7/14/26 | bladder cancertreatment options+3 | Dr. Adam J. Gadzinski | — | — | bladder cancernon-muscle-invasive+3 | Urogen | 49m 07s | ||
| 7/10/26 | private equityurology practices+4 | Dr. Benjamin Lowentritt | Chesapeake UrologyUnited Urology Group | — | private equityurology+5 | — | 48m 45s | ||
| 7/7/26 | PARP inhibitorsprostate cancer+4 | Dr. Rana McKayDr. Emmanuel Antonarakis | PROpelMAGNITUDE+3 | — | PARP inhibitorsprostate cancer+6 | Pfizer | 51m 39s | ||
| 6/30/26 | pelvic lymph node dissectionprostate cancer surgery+4 | Dr. Kirsten Greene | BackTable | — | pelvic lymph node dissectionprostate cancer+3 | — | 35m 43s | ||
| 6/25/26 | intravesical therapybladder cancer+4 | Mary DunnMeredith Donahue | UNCVanderbilt+1 | — | bladder cancerintravesical therapy+4 | Johnson & Johnson | 30m 37s | ||
| 6/23/26 | career diversificationurology+5 | Dr. Kelly ParsonsDr. Pat Keegan | BackTable | — | urologistsbiotech+5 | — | 54m 31s | ||
| 6/18/26 | bladder cancerrisk stratification+3 | Dr. Sunil PatelDr. Kristen Scarpato | — | — | bladder cancerrisk assessment+3 | Johnson & Johnson | 43m 31s | ||
| 6/16/26 | robotic reconstructive surgeryminimally invasive procedures+3 | Dr. Ziho Lee | BackTable UrologyBackTable+1 | — | roboticsurology+5 | — | 43m 24s | ||
| 6/11/26 | shared decision-makingbladder cancer treatment+5 | Dr. Kelly BreeDr. Meredith Donahue+1 | — | — | bladder cancerNMIBC+5 | Johnson & Johnson | 48m 23s | ||
| 6/9/26 | somatic testingprostate cancer+4 | Dr. Tanya DorffDr. Evan Yu | — | — | BRCA2PARP inhibitors+7 | Pfizer | 40m 51s | ||
| 6/4/26 | bladder cancerco-managed clinics+3 | Dr. Amy LuckenbaughMeredith Donahue DNP | — | — | bladder cancerco-managed clinics+5 | Johnson & Johnson | 44m 37s | ||
| 6/2/26 | immunotherapybladder cancer+4 | Dr. Sam Chang | AnktivaN-803+3 | BCGNMIBC | BCGimmunotherapy+4 | ImmunityBio | 48m 58s | ||
| 5/26/26 | urological incontinenceoffice protocols+3 | Dr. Michael KennellyDr. Jason Kim | Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction | — | urological incontinenceoveractive bladder+5 | — | 41m 39s | ||
| 5/19/26 | PARP inhibitorsadvanced prostate cancer+4 | Dr. Neeraj AgarwalDr. Arun Azad | — | — | PARP inhibitorsanemia+5 | Pfizer | 1h 15m 29s | ||
| 5/12/26 | male infertilitydiagnosis+5 | Dr. Robert E. Brannigan | AUAASRM+1 | — | male factor infertilitysemen analysis+5 | — | 46m 50s | ||
| 5/5/26 | biomarkersprostate cancer+4 | Dr. Udit Singhal | University of MichiganVanderbilt University | — | biomarkersprostate cancer+5 | Veracyte | 34m 32s | ||
| 4/28/26 | Renal Cell CarcinomaVenous Tumor Thrombus+4 | Dr. Vidit Sharma | Mayo Clinic | — | Renal Cell CarcinomaVenous Tumor Thrombus+6 | — | 1h 43m 51s | ||
| 4/21/26 | urodynamicsstress incontinence+3 | Dr. Howard GoldmanDr. David Ginsberg | — | — | urodynamicsmanagement+5 | — | 52m 15s |
Showing 20 of 20
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for BackTable Urology
Peaked at #47 in PT, currently #47 in PT.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| PT | — | #47 | #47 | — |
| Mexico | — | #99 | #99 | — |
| TR | — | #103 | #103 | — |
| TH | — | #115 | #115 | — |
| Canada | — | #175 | #175 | — |
| United Kingdom | — | #185 | #185 | — |
Chart Positions
6 placements across 6 markets.
Chart Positions
6 placements across 6 markets.